{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:49:13Z","timestamp":1760622553617},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.2515\/therapie:2004030","type":"journal-article","created":{"date-parts":[[2007,3,14]],"date-time":"2007-03-14T15:42:11Z","timestamp":1173886931000},"page":"155-162","source":"Crossref","is-referenced-by-count":2,"title":["Une mod\u00e9lisation informatique pour une meilleure compr\u00e9hension de la relation PK\/PD : application \u00e0 l\u2019azithromycine dans le traitement de l\u2019angine aigu\u00eb streptococcique et des exacerbations aigu\u00ebs de la bronchite chronique"],"prefix":"10.1016","volume":"59","author":[{"given":"Yves","family":"Le Normand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Drugeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Palestro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2004030_bb4065","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0924-8579(02)00031-6","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs","volume":"19","author":"Mouton","year":"2002","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 1","key":"10.2515\/therapie:2004030_bb4070","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0924-8579(01)00406-X","article-title":"Macrolides: pharmacokinetics and pharmacodynamics","volume":"18","author":"Van Bambeke","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.2515\/therapie:2004030_bb4075","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2165\/00044011-199713030-00005","article-title":"Comparison of the plasma, urine and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects","volume":"13","author":"Amsden","year":"1997","journal-title":"Clin Drug Invest"},{"key":"10.2515\/therapie:2004030_bb4080","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jac\/26.4.533","article-title":"The pharmacokinetics and inflammatory fluid penetration of orally administered azithromycin","volume":"26","author":"Cooper","year":"1990","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. A","key":"10.2515\/therapie:2004030_bb4085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","article-title":"The pharmacokinetics of azithromycin in human serum and tissues","volume":"25","author":"Foulds","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.2515\/therapie:2004030_bb4090","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0399-077X(05)80405-6","article-title":"Propri\u00e9t\u00e9s pharmacocin\u00e9tiques des nouveaux macrolides. A propos de l\u2019azithromycine","volume":"25","author":"Fourtillan","year":"1995","journal-title":"M\u00e9d Mal Infect"},{"issue":"Suppl. E","key":"10.2515\/therapie:2004030_bb4095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/31.suppl_E.57","article-title":"Pharmacokinetics of azithromycin in patients with impaired hepatic function","volume":"31","author":"Mazzei","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.2515\/therapie:2004030_bb4100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000239473","article-title":"A linear model for the pharmacokinetics of azithromycin in healthy volunteers","volume":"42","author":"Ripa","year":"1996","journal-title":"Chemotherapy"},{"issue":"Suppl. E","key":"10.2515\/therapie:2004030_bb4105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/jac\/31.suppl_E.51","article-title":"Comparison of the pharmacokinetics of three-day and five-day regimens of azithromycin in plasma and urine","volume":"31","author":"Wildfeuer","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.2515\/therapie:2004030_bb4110","first-page":"356","article-title":"Distribution of orally administered azithromycin in various blood compartments","volume":"32","author":"Wildfeuer","year":"1994","journal-title":"Int J Clin Pharmacol Therap"},{"key":"10.2515\/therapie:2004030_bb4115","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.2515\/therapie:2004030_bb4120","series-title":"Clinical pharmacokinetics","author":"Rowland","year":"1989"},{"key":"10.2515\/therapie:2004030_bb4125","series-title":"Contribution au dossier d\u2019autorisation de mise sur le march\u00e9 (AMM)","article-title":"Simulation de la pharmacocin\u00e9tique de l\u2019azithromycine (Zithromax\u00ae)","author":"Le Normand","year":"1999"},{"key":"10.2515\/therapie:2004030_bb4130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0020-7101(94)90101-5","article-title":"Teaching individualized antibiotic dosage regimens by means of two computer-assisted programs","volume":"36","author":"Le Normand","year":"1994","journal-title":"Int J Biomed Comput"},{"issue":"Suppl. 3","key":"10.2515\/therapie:2004030_bb4135","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0014-2999(90)92760-G","article-title":"Tobra-Didact: a computer program for teaching individual adaptation of tobramycin therapy","volume":"183","author":"Le Normand","year":"1990","journal-title":"Eur J Pharmacol"},{"issue":"Suppl. 3A","key":"10.2515\/therapie:2004030_bb4140","doi-asserted-by":"crossref","first-page":"5S","DOI":"10.1016\/0002-9343(91)90394-D","article-title":"Tissue-directed pharmacokinetics","volume":"91","author":"Schentag","year":"1991","journal-title":"Am J Med"},{"key":"10.2515\/therapie:2004030_bb4145","unstructured":"Singlas E. Etude de la diffusion amygdalienne de l\u2019azithromycine administr\u00e9e par voie orale pendant 3 jours. Dossier d\u2019autorisation de mise sur le march\u00e9 (AMM) : Etude AZM-F-92001."},{"key":"10.2515\/therapie:2004030_bb4150","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1128\/AAC.36.6.1176","article-title":"Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance","volume":"36","author":"Baldwin","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2004030_bb4155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0399-077X(05)81459-3","article-title":"Pharmacocin\u00e9tique des antibiotiques dans les voies respiratoires inf\u00e9rieures. Limites de l\u2019apport de cette information","volume":"22","author":"Bergogne-B\u00e9r\u00e9zin","year":"1992","journal-title":"M\u00e9d Mal Infect"},{"issue":"Suppl. 2","key":"10.2515\/therapie:2004030_bb4160","first-page":"S43","article-title":"Cin\u00e9tique de distribution des antibiotiques dans la sph\u00e8re bronchopulmonaire","volume":"52","author":"Fourtillan","year":"1996","journal-title":"Rev Pneumol Clin"},{"key":"10.2515\/therapie:2004030_bb4165","series-title":"Macrolides: chemistry, pharmacology and clinical uses","first-page":"197","article-title":"Activity of macrolides against common pathogens in vitro","author":"Neu","year":"1993"},{"key":"10.2515\/therapie:2004030_bb4170","series-title":"Macrolides: chemistry, pharmacology and clinical uses","first-page":"229","article-title":"Biology and experimental chemotherapy of Legionella infections","author":"Hacker","year":"1993"},{"key":"10.2515\/therapie:2004030_bb4175","series-title":"Macrolides: chemistry, pharmacology and clinical uses","first-page":"253","article-title":"Antimycoplasmal activity of macrolides","author":"Orfila","year":"1993"},{"key":"10.2515\/therapie:2004030_bb4180","series-title":"Macrolides: chemistry, pharmacology and clinical uses","first-page":"241","article-title":"Chlamydial infections","author":"Orfila","year":"1993"},{"issue":"Suppl. E","key":"10.2515\/therapie:2004030_bb4185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jac\/31.suppl_E.39","article-title":"Selection of dose regimens of azithromycin","volume":"31","author":"Foulds","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.2515\/therapie:2004030_bb4190","unstructured":"Fourtillan JB. Pharmacokinetic handling of azithromycin after administration of oral and intravenous single doses, and multiple dosing in 12 healthy volunteers. Dossier d\u2019autorisation de mise sur le march\u00e9 (AMM) : Etude AZM-F-93004"},{"key":"10.2515\/therapie:2004030_bb4195","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00006454-199704000-00027","article-title":"Pharmacokinetics and pharmacodynamics of newer macrolides","volume":"16","author":"Nightingale","year":"1997","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl. 3","key":"10.2515\/therapie:2004030_bb4200","first-page":"38","article-title":"Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections","volume":"9","author":"Drusano","year":"1997","journal-title":"J Chemother"},{"key":"10.2515\/therapie:2004030_bb4205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie:2004030_bb4210","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1086\/321854","article-title":"Does the dose matter?","volume":"33","author":"Craig","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie:2004030_bb4215","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1128\/AAC.41.6.1399","article-title":"Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers","volume":"41","author":"Rodvold","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2004030_bb4220","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1128\/AAC.40.10.2375","article-title":"Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin","volume":"40","author":"Patel","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2004030_bb4225","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1183\/09031936.93.03080886","article-title":"Azithromycin concentrations at the sites of pulmonary infection","volume":"3","author":"Baldwin","year":"1990","journal-title":"Eur Respir J"},{"key":"10.2515\/therapie:2004030_bb4230","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1128\/AAC.40.11.2582","article-title":"Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses","volume":"40","author":"Olsen","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2004030_bb4235","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1128\/AAC.40.7.1617","article-title":"Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects","volume":"40","author":"Conte","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie:2004030_bb4240","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0891-5520(05)70202-6","article-title":"Intrapulmonary concentrations of antimicrobial agents","volume":"12","author":"Nix","year":"1998","journal-title":"Infect Dis Clin North Am"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716301755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716301755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:25:09Z","timestamp":1683764709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716301755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S0040595716301755"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2004030","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]}}}